Filing Flows › Korsana Biosciences (KRSA) › Q3 2025
Korsana Biosciences (KRSA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Korsana Biosciences (KRSA) reported revenue of $875K for the third quarter 2025 (Q3 2025), +351% from a year earlier and +841% from the quarter before. Operating margin was -115.0%, net loss $976K (111.5% of revenue).
Korsana Biosciences, Q3 2025: revenue $875K (+351% year over year), operating margin -115.0%, net loss $976K, operating cash flow −$264K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $875K | +841% | +351% |
| Operating profit | −$1.0M | — | — |
| Net earnings | −$976K | — | — |
| Operating cash flow | −$264K | — | — |
What changed
Revenue was $875K in Q3 2025, up 351% year over year and up 841% from the previous quarter. Purchase Agreement was the largest line at 91% of revenue. Option Agreement declined 61%.
Operating costs exceeded revenue by $1.0M, an operating margin of -115.0%. Total costs grew 42% against revenue growth of 351%. The fastest-growing cost line was Research & development (+330%). The quarter ended with a net loss of $1.0M, wider than the previous quarter's $324K loss.
Operating cash flow was −$264K. Non-cash charges added back $118K of share-based compensation. Working capital and other items added $594K.
Questions
What was Korsana Biosciences' revenue in the third quarter 2025?
Korsana Biosciences (KRSA) reported revenue of $875K for the third quarter 2025 (Q3 2025), +351% from a year earlier and +841% from the quarter before.
Was Korsana Biosciences profitable in the third quarter 2025?
Operating loss was $1.0M (-115.0% of revenue) and net loss $976K.